 |
| Weekly Journal Scans | More » |
 |
Meta-analysis of Bleeding Risk With Sunitinib and Sorafenib
Lancet Oncol, 2009 Oct 1, Y Je , et al
Large meta-analysis showing that sunitinib and sorafenib significantly increase bleeding risk suggests careful surveillance for this potential risk is warranted.
|
High Id1 Expression Indicates Poor Prognosis in AML
Blood, 2009 Oct 1, R Tang, et al
In patients with AML, especially those aged 60 years or younger, high Id1 expression independently predicted shorter DFS and OS.
|
Assessing CML Complete Cytogenetic Response With I-FISH vs Chromosome Banding
Blood, 2009 Oct 1, N Testoni, et al
I-FISH is more sensitive than chromosome banding analysis and can be used to monitor complete cytogenetic response.
|
Abnormal FLC Ratio in Multiple Myeloma May Change Stringent CR Definition
Blood, 2009 Oct 1, C Fernandez de Larrea , et al
In patients with MM in CR, the presence of oligoclonal bands frequently results in an abnormal FLC ratio.
|
NPM1 Mutation Is a Defining Molecular Feature in AML
Blood, 2009 Oct 1, C Haferlach, et al
New data strongly suggest NPM1 mutation is the founder genetic lesion in AML; chromosomal aberrations appear to be secondary events.
|
Triple-Negative Breast Cancer Has Higher VEGF Levels and Worse Prognosis
Ann Oncol, 2009 Oct 1, BK Linderholm, et al
This study evaluated survival and VEGF levels in triple-negative and non−triple-negative breast cancer.
|
Rate of Cytoreductive Nephrectomy for Metastatic RCC in the US
Urology, 2009 Oct 1, C Jeldres, et al
Although cytoreductive nephrectomy improves survival in patients with RCC, racial and geographic variability in its use is worrisome.
|
Dynamic Prognostic Model Predicts Highest-Risk Disease in Myelofibrosis
J Clin Oncol, 2009 Sept 28, C Tam, et al
A dynamic model based on acute-phase criteria predicted patients with median survival of 12 months or less at any time during the disease course.
|
Lapatinib/Letrozole Superior to Letrozole in HER2+/HR+ Metastatic Breast Cancer
J Clin Oncol, 2009 Sept 28, S Johnston, et al
Phase III trial demonstrates superiority of lapatinib/letrozole over letrozole alone in HER2+/HR+ metastatic breast cancer.
|
Maintenance With Simplified LV5FU2 vs Chemotherapy Discontinuation in Unresectable Metastatic Colorectal Cancer
J Clin Oncol, 2009 Sept 28, B Chibaudel, et al
EXPERT COMMENTARY
Maintenance CT between induction therapy with and reintroduction of mFOLFOX7 reduces risk of oxaliplatin failure vs a CT-free interval.
|
Efficacy and Safety of Carboplatin-Based Therapy in Advanced Urothelial Cancer
J Clin Oncol, 2009 Sept 28, M De Santis, et al
Phase II results indicate the feasibility of carboplatin-based chemotherapy in patients "unfit" to withstand cisplatin-based therapy.
|
Tamoxifen Is Comparable to Raloxifene in Effects on Cognition
J Clin Oncol, 2009 Sept 21, C Legault, et al
Tamoxifen and raloxifene did not significantly differ in their effects on cognitive function.
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
| |
|
|
| | |
| CANCER POLICY FORUM
Get behind-the-headline perspectives on the politics of cancer.
VISIT SITE
| |
|
|
| | |
| WHEN THE SMOKE CLEARS
Experts discuss the true clinical implications of watershed developments in oncology research.
VISIT SITE
| |
|
|
| | |
| RELATED WEBSITES
These websites offer more information on a variety of oncology-related topics.
VISIT SITE
| |
|
|
| | |
| VIDEOS
Watch video interviews with leading cancer experts.
VISIT SITE
| |
|
|
|
A Week in Review
